<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02813044</url>
  </required_header>
  <id_info>
    <org_study_id>4-2016-0344</org_study_id>
    <nct_id>NCT02813044</nct_id>
  </id_info>
  <brief_title>Effects of Total Intravenous Anesthesia With Propofol-remifentanil Versus Inhalational Anesthesia With Sevoflurane on Quality of Recovery in Patients Undergoing Transsphenoidal Surgery for Pituitary Tumor</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A number of studies have compared the effects of total intravenous anesthesia(TIVA) versus
      inhalational anesthesia on perioperative period during transsphenoidal surgery. However, they
      have limitations especially for the phase of recovery after anesthesia: a fragmentary
      assessment. Quality of Recovery 40 (QoR-40) questionnaire was multi-dimensionally designed to
      assess the degree of recovery, specially after anesthesia and surgery. In this study, the
      investigators aim to compare the quality of recovery after inhalational anesthesia and after
      TIVA through QoR-40 questionnaire in patients undergoing transsphenoidal surgery for
      pituitary tumor under general anesthesia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QoR-40 score</measure>
    <time_frame>1 day</time_frame>
    <description>We compare the QoR-40 scores of two groups 1 day after the operation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Pituitary Tumor</condition>
  <arm_group>
    <arm_group_label>TIVA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anesthesia is maintained with propofol during surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inhalation anesthesia group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anesthesia is maintained with sevoflurane during surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>total intravenous anesthesia (TIVA)</intervention_name>
    <description>In the TIVA group,anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil.</description>
    <arm_group_label>TIVA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhalation anesthesia group</intervention_name>
    <description>In the inhalation anesthesia group, anesthesia is induced by pentothal sodium 4-6mg/kg and remifentanil 1 μg/kg, and then maintained with end-tidal sevoflurane concentration of 0.8 to 1 MAC and continuous infusion of remifentanil at 0.1-0.3μg/kg/min.</description>
    <arm_group_label>inhalation anesthesia group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over age 19

          -  Scheduled to undergo transsphenoidal surgery for pituitary tumor

          -  ASA class I and II

        Exclusion Criteria:

          -  Left ventricular ejection fraction &lt; 55%

          -  Third-degree atrioventricular block

          -  Second-degree atrioventricular block (P:QRS ratio of 3:1 or higher)

          -  Fever

          -  History of myocardial infarction, stroke or cardiac surgery within the previous 1 year

          -  Severe neurological disease

          -  Use of sedative, opioid or sleep-inducing drugs

          -  Allergic history of any study drug

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Associate Professor Department of Anesthesiology and Pain Medicine,</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Ho Cho, Ph.D</last_name>
      <phone>82-2-2228-2427</phone>
      <email>csho99@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Al-Shaikh B, George William M, Van Zundert AA. Using atmospheric pressure to inflate the cuff of the Portex Laryngeal Mask. Anaesthesia. 2005 Mar;60(3):296-7.</citation>
    <PMID>15710025</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>June 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2016</study_first_posted>
  <last_update_submitted>December 29, 2016</last_update_submitted>
  <last_update_submitted_qc>December 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anesthesia</keyword>
  <keyword>intravenous</keyword>
  <keyword>neurosurgery</keyword>
  <keyword>pituitary neoplasm</keyword>
  <keyword>postoperative period</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

